Purdue Pharma LP
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1892-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.purduepharma.com
The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers
- Conditions
- ECG Effects
- Interventions
- Drug: Placebos (for TDS and for naltrexone and for moxifloxacin)
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 328
- Registration Number
- NCT01999114
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
An Analgesic Study to of V117957 for the Treatment of Postsurgical Pain Due to Third Molar Extraction
- Conditions
- Postsurgical Pain Due to Third Molar Extraction
- Interventions
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 114
- Registration Number
- NCT01900795
- Locations
- 🇺🇸
PPD Dental Pain Clinic, Austin, Texas, United States
Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)
- Conditions
- Postherpetic NeuralgiaPain
- Interventions
- First Posted Date
- 2012-09-20
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 105
- Registration Number
- NCT01688947
- Locations
- 🇺🇸
Investigational Site, Salt Lake City, Utah, United States
Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee
- Conditions
- Osteoarthritis, KneePain
- Interventions
- First Posted Date
- 2012-09-20
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 230
- Registration Number
- NCT01688934
- Locations
- 🇺🇸
Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
🇺🇸Avail Clinical Research, LLC, Deland, Florida, United States
🇺🇸Westside Center for Clinical Research, Jacksonville, Florida, United States
Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain
- Conditions
- Chronic Low Back Pain
- Interventions
- Drug: Placebo to match hydrocodone bitartrate q24h tablets
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 905
- Registration Number
- NCT01452529
- Locations
- 🇺🇸
Coastal Clinical Research, Inc., Mobile, Alabama, United States
🇺🇸Meridien Research, Bradenton, Florida, United States
🇺🇸Gold Coast Research, LLC, Plantation, Florida, United States
A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain
- Conditions
- Low Back Pain
- Interventions
- First Posted Date
- 2011-09-01
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 450
- Registration Number
- NCT01427283
- Locations
- 🇺🇸
Investigational Site, Bothell, Washington, United States
Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain
- Conditions
- Low Back Pain
- Interventions
- First Posted Date
- 2011-09-01
- Last Posted Date
- 2014-11-07
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 455
- Registration Number
- NCT01427270
- Locations
- 🇵🇱
Investigational Site, Torun, Poland
Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.
- Conditions
- Chronic Nonmalignant and Nonneuropathic Pain
- Interventions
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 922
- Registration Number
- NCT01400139
- Locations
- 🇺🇸
Bone Joint and Spine Surgeons, Inc., Toledo, Ohio, United States
🇺🇸Research Across America, New York, New York, United States
🇺🇸Upstate Clinical Research Associates, Williamsville, New York, United States
Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 23
- Registration Number
- NCT01369615
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Bayview Research Group, LLC, Paramount, California, United States
🇺🇸Mercy Clinic Children's Cancer and Hematology Center, St. Louis, Missouri, United States
Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain
- Conditions
- Low Back Pain
- Interventions
- Drug: Oxycodone/Naloxone Controlled-releaseDrug: Placebo
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 1095
- Registration Number
- NCT01358526
- Locations
- 🇺🇸
South Orange County Surgical Medical Group, Laguna Hills, California, United States
🇺🇸Probe Clinical Research Corporation, Santa Ana, California, United States
🇺🇸Innovative Research of West Florida, Inc., Clearwater, Florida, United States